Skip to main content

Advertisement

Table 1 Results of the cost–effectiveness analyses

From: Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients

  Lifetime costs (€) Lifetime QALYs ICER (€/QALY gained)
Apixaban Warfarin Diff. Apixaban Warfarin Diff.
Base case 16,197 15,936 261 7.19 7.05 0.14 1824
Without discounting 20,647 20,442 205 8.99 8.80 0.19 1060
Sensitivity analyses
CHADS 0–1 15,491 14,931 560 7.25 7.12 0.13 4347
CHADS 2 16,151 15,708 443 7.20 7.07 0.13 3387
CHADS 3–6 17,012 17,266 −254 7.13 6.96 0.17 Dominant
TTR < 52.38 % 16,047 17,150 −1104 7.19 6.97 0.22 Dominant
52.38 % ≤ TTR < 66.02 % 17,397 16,170 1226 7.14 7.04 0.10 12,312
66.02 % ≤ TTR < 76.51 % 16,164 15,131 1033 7.20 7.10 0.10 10,386
TTR ≥ 76.51 % 15,150 15,249 −98.23 7.25 7.10 0.15 Dominant
No treatment discontinuations after trial period 19,473 19,042 431 7.24 7.04 0.21 2102
Warfarin monitoring cost −50 % 16,197 14,650 1546 7.19 7.05 0.15 10,817
Warfarin monitoring cost +50 % 16,197 17,222 −1025 7.19 7.05 0.14 Dominant